By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Rybelsus vs Wegovy pill: two pills, one active ingredient
Rybelsus vs Wegovy pill is a question I hear almost every day in my clinic. Both pills contain semaglutide, the active ingredient in Ozempic and Wegovy. However, they differ in dose, in purpose and in the people they are meant for. In recent years, GLP-1 drugs have transformed the treatment of obesity and type 2 diabetes. Now the revolution is moving from the injection to the daily pill.
What is semaglutide, and why does it matter so much?
Semaglutide is a near-identical copy of the hormone GLP-1. Normally, the gut releases this hormone after a meal. It acts on the hunger and fullness centers in the brain, on the pancreas and on the digestive system. As a result, it boosts insulin release when blood sugar rises, slows stomach emptying and reduces hunger. Together, these effects lead to better blood sugar control, weight loss and a lower risk of heart and blood vessel disease. I explain the mechanism in depth in my article on semaglutide and the heart.
Rybelsus: the first semaglutide pill
Rybelsus was the first pill to bring semaglutide into treatment. Its approval covers type 2 diabetes, and you take it once a day. In the PIONEER 1 trial, the 14 mg dose lowered HbA1c, the average blood sugar over the past three months, by 1.1% more than placebo. Weight, by contrast, fell by only 2.3 kg more than placebo. That is why doctors do not consider Rybelsus a weight-loss drug.
Then, in 2025, Rybelsus gained an important benefit. The SOUL trial showed a 14% lower risk of major cardiac events in high-risk people with diabetes. Following it, the U.S. Food and Drug Administration (FDA) added a heart-protection indication to Rybelsus. I also explain its effect on weight in my article on Rybelsus and weight loss.
The Wegovy pill: the first pill for obesity
In December 2025, the FDA approved the Wegovy pill, semaglutide at 25 mg a day. The OASIS 4 trial enrolled 307 adults with overweight or obesity and no diabetes. After 64 weeks, participants on the pill lost an average of 13.6% of their body weight. In the placebo group, by contrast, the loss was 2.2%. For comparison, in the STEP 1 trial, the Wegovy injection led to 14.9% weight loss after 68 weeks. In other words, the pill comes very close to the injection. I answer common questions about the new pills in my article on weight-loss pills.
I cover that decision in detail in my article on the Wegovy pill FDA approval.
Rybelsus vs Wegovy pill: the key differences
The first difference is the goal. Rybelsus aims to control diabetes, while the Wegovy pill aims to treat obesity. The second difference is the dose: 25 mg in the Wegovy pill, compared with up to 14 mg in the original Rybelsus. In the new Rybelsus formulation, the equivalent dose is 9 mg. The third difference concerns the population. Notably, researchers tested the Wegovy pill specifically in people without diabetes.
At the same time, the two pills have a lot in common. Both use the same carrier, SNAC, which helps absorption through the stomach. Therefore, the instructions are identical: in the morning, on an empty stomach, with up to 120 ml of water. Then you wait half an hour before eating, drinking or taking other medications.
Side effects and adherence
With both pills, the side effects are similar to those of the injections. For the most part, these are nausea, vomiting and diarrhea. In OASIS 4, digestive symptoms occurred in 74.0% of people on the pill, compared with 42.2% on placebo. In most cases they were mild to moderate. Outside a trial, however, adherence may drop because of these symptoms and because you must take the pill precisely. That is why a gradual dose increase is especially important.
Competition and the future
Still, the shift to pills is not the end of the story. In April 2026, the FDA approved Foundayo from Eli Lilly. This is orforglipron, a non-peptide GLP-1 pill that you can take at any time of day, with no food restrictions. I compare the options in my article on Foundayo vs oral semaglutide.
On the economic side, Goldman Sachs estimated in May 2025 that the global market would reach $95 billion by 2030. According to the same estimate, pills will capture about a quarter of the market. In other words, injections will remain relevant for years to come.
What about Israel?
Obesity counts as a chronic disease, yet the national health basket still does not cover most obesity drugs for adults. The 2026 health basket added the Wegovy injection only for adolescents aged 12 to 18. Adults buy these drugs at a discount through the supplementary insurance plans of Israel’s health funds (HMOs), but the price is still high for many. The Wegovy pill arrived in Israel in November 2026 and is available through Form 29C, the Ministry of Health pathway for medications not yet registered in Israel.
Rybelsus vs Wegovy pill: how to choose
First of all, the choice starts with the diagnosis. A person with diabetes who mainly needs blood sugar control and heart protection will usually be a good fit for Rybelsus. On the other hand, a person with obesity, with or without diabetes, who needs significant weight loss will usually be better suited to a dedicated obesity treatment. For some, that means an injection, as I explain in who needs high-dose Wegovy. Either way, you make the final decision with your doctor, based on your goals, other health conditions and cost.
Not a magic pill
Alongside the excitement, it is important to keep things in proportion. GLP-1 drugs, whether injected or swallowed, are powerful tools, but they are not a magic fix. Safe, lasting success requires close medical follow-up, tailored nutrition, physical activity and multidisciplinary support. Ultimately, the move from injection to pill opens a door for many people. Our medical responsibility, however, stays the same: to see the whole person, not just the weight.
The bottom line: Rybelsus vs Wegovy pill
Rybelsus vs Wegovy pill is not a contest between good and bad. Instead, these are two tools with the same active ingredient and different goals. Rybelsus controls diabetes and protects the heart, while the Wegovy pill leads to an average weight loss of 13.6%. In the end, personal fit is what decides.
This article provides general information and is not a substitute for personal medical advice.
References
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity
The anti-obesity drug market may prove smaller than expected
The PIONEER 1, SOUL, OASIS 4 and STEP 1 trials were funded by Novo Nordisk, the manufacturer of the drugs.
